{"disease":{"id":"olverembatinib","name":"olverembatinib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07178912","title":"Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07282093","title":"Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05311943","title":"Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}